Market Summary
USD37.69-0.51
Market Closed-1.34%
HALO Stock Price
HALO RSI Chart
HALO Valuation
HALO Price/Sales (Trailing)
HALO Profitability
HALO Fundamentals
HALO Revenue
HALO Earnings
Price Action
52 Week Range
29.8559.46
(Low)(High)
Last 7 days
-3.1%
Last 30 days
-12.0%
Last 90 days
2.2%
Trailing 12 Months
-4.7%
HALO Financial Health
HALO Investor Care
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
Get all data in R, Python etc through our Historical Stock Data APIs
Latest Insider Trading transactions for HALO
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-09-19 | LaBarre Michael J. | acquired | 199,800 | 19.98 | 10,000 | svp, chief technical officer |
2023-09-19 | LaBarre Michael J. | sold | -390,980 | 39.098 | -10,000 | svp, chief technical officer |
2023-08-31 | Torley Helen | sold | -428,170 | 42.817 | -10,000 | president and ceo |
2023-08-31 | Torley Helen | acquired | 138,700 | 13.87 | 10,000 | president and ceo |
2023-08-30 | Torley Helen | acquired | 138,700 | 13.87 | 10,000 | president and ceo |
2023-08-30 | Torley Helen | sold | -428,540 | 42.854 | -10,000 | president and ceo |
2023-08-29 | Torley Helen | sold | -424,020 | 42.402 | -10,000 | president and ceo |
2023-08-29 | Torley Helen | acquired | 138,700 | 13.87 | 10,000 | president and ceo |
2023-08-22 | LaBarre Michael J. | acquired | 196,778 | 19.6778 | 10,000 | svp, chief technical officer |
2023-08-22 | LaBarre Michael J. | sold | -424,070 | 42.407 | -10,000 | svp, chief technical officer |
Which funds bought or sold HALO recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-09-20 | BARCLAYS PLC | added | 44.29 | 2,695,000 | 10,129,000 | 0.01% |
2023-09-18 | WASHINGTON CAPITAL MANAGEMENT, INC | unchanged | - | -32,860 | 559,085 | 0.48% |
2023-09-12 | Farther Finance Advisors, LLC | added | 500 | 891 | 1,082 | -% |
2023-08-29 | EFG Asset Management (Americas) Corp. | added | 20.00 | 34,005 | 288,885 | 0.07% |
2023-08-24 | Alberta Investment Management Corp | new | - | 558,003 | 558,003 | -% |
2023-08-23 | Rehmann Capital Advisory Group | unchanged | - | -745 | 36,545 | -% |
2023-08-22 | VIRGINIA RETIREMENT SYSTEMS ET AL | reduced | -95.00 | -7,641,160 | 378,735 | -% |
2023-08-21 | OSAIC HOLDINGS, INC. | added | 32.2 | 121,837 | 594,734 | -% |
2023-08-21 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | reduced | -6.95 | -813,053 | 5,900,370 | 0.01% |
2023-08-21 | TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY | added | 10.27 | 35,000 | 879,000 | 0.01% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
Schedule 13G FIlings of Halozyme Therapeutics
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Jun 09, 2023 | vanguard group inc | 10.27% | 13,528,630 | SC 13G/A | |
| Feb 10, 2023 | invesco ltd. | 5.2% | 7,036,951 | SC 13G | |
| Feb 10, 2023 | blackrock inc. | 14.2% | 19,196,061 | SC 13G/A | |
| Feb 10, 2023 | artisan partners limited partnership | 5.3% | 7,140,953 | SC 13G/A | |
| Feb 09, 2023 | vanguard group inc | 9.84% | 13,303,847 | SC 13G/A | |
| Jan 26, 2023 | blackrock inc. | 13.6% | 18,214,071 | SC 13G/A | |
| Jan 20, 2023 | blackrock inc. | 13.6% | 18,214,071 | SC 13G | |
| Feb 04, 2022 | artisan partners limited partnership | 6.8% | 9,505,768 | SC 13G/A | |
| Jan 28, 2022 | blackrock inc. | 13.8% | 19,439,863 | SC 13G/A | |
| Feb 12, 2021 | bb biotech ag | 2.9% | 3,970,000 | SC 13G/A |
Recent SEC filings of Halozyme Therapeutics
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Sep 19, 2023 | 144 | Notice of Insider Sale Intent | |
| Sep 19, 2023 | 4 | Insider Trading | |
| Sep 07, 2023 | 8-K | Current Report | |
| Aug 31, 2023 | 144 | Notice of Insider Sale Intent | |
| Aug 31, 2023 | 4 | Insider Trading | |
| Aug 30, 2023 | 144 | Notice of Insider Sale Intent | |
| Aug 29, 2023 | 144 | Notice of Insider Sale Intent | |
| Aug 23, 2023 | 4 | Insider Trading | |
| Aug 22, 2023 | 144 | Notice of Insider Sale Intent | |
| Aug 17, 2023 | 4 | Insider Trading |
Peers (Alternatives to Halozyme Therapeutics)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
AMGN | 142.4B | 26.6B | 3.74% | 20.01% | 17.85 | 5.36 | 0.75% | 21.34% |
GILD | 92.4B | 27.4B | -3.33% | 22.27% | 16.85 | 3.37 | -0.48% | 32.56% |
MRNA | 39.4B | 10.7B | -8.22% | -12.63% | 32.61 | 3.69 | -53.67% | -91.41% |
BIIB | 36.6B | 10.0B | -5.36% | -5.30% | 13.73 | 3.67 | -6.23% | 29.40% |
| MID-CAP | ||||||||
NBIX | 10.9B | 1.7B | 1.05% | 5.25% | 61.85 | 6.52 | 29.01% | 1345.90% |
BBIO | 4.1B | - | -16.91% | 155.63% | -7.02 | 48.33 | 54.84% | -12.96% |
DNLI | 2.7B | - | -15.10% | -35.52% | -21.18 | 37.44 | 122.90% | 54.78% |
BEAM | 1.7B | 80.2M | -8.35% | -54.87% | -5.12 | 20.91 | 42.17% | -39.82% |
| SMALL-CAP | ||||||||
RCUS | 1.3B | 121.2M | -18.44% | -33.91% | -4.48 | 10.62 | -70.36% | -531.73% |
REPL | 931.2M | 15.3M | -19.93% | -8.57% | -5.13 | 60.82 | 1090.59% | -36.57% |
NVAX | 668.6M | 1.6B | -13.64% | -61.04% | -1.14 | 0.42 | 23.74% | 60.24% |
FATE | 189.2M | - | -31.67% | -91.43% | -0.89 | 1.38 | 116.83% | 16.61% |
VXRT | 113.0M | 2.1M | -10.53% | -65.89% | -1.12 | 55 | 487.70% | -8.66% |
SGMO | 104.6M | - | -38.94% | -87.76% | -0.53 | 0.43 | 113.96% | -15.19% |
IBIO | 6.3M | - | 5.48% | -92.77% | -0.08 | 3.21 | - | -129.46% |
Halozyme Therapeutics News
Returns for HALO
Cumulative Returns on HALO
13.2%
10-Year Cumulative Returns
17.4%
7-Year Cumulative Returns
15.1%
5-Year Cumulative Returns
13.5%
3-Year Cumulative Returns
Risks for HALO
What is the probability of a big loss on HALO?
85.4%
Probability that Halozyme Therapeutics stock will be more than 20% underwater in next one year
28.5%
Probability that Halozyme Therapeutics stock will be more than 30% underwater in next one year.
11.2%
Probability that Halozyme Therapeutics stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does HALO drawdown profile look like?
Y-axis is the maximum loss one would have experienced if Halozyme Therapeutics was unfortunately bought at previous high price.
Drawdowns
Financials for Halozyme Therapeutics
Income Statement (Last 12 Months)(In Millions)
| Income Statement (Last 12 Months) | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Revenue | 9.7% | 774 | 705 | 660 | 581 | 487 | 472 | 443 | 463 | 412 | 331 | 268 | 200 | 180 | 164 | 196 | 203 | 182 | 178 | 152 | 281 | 319 |
| Costs and Expenses | 1.8% | 468 | 459 | 393 | 331 | 246 | 171 | 167 | 166 | 151 | 133 | 123 | 165 | 211 | 238 | 264 | 238 | 218 | 221 | 221 | 225 | 229 |
| S&GA Expenses | -11.1% | 149 | 167 | 144 | 120 | 98.00 | 53.00 | 50.00 | 47.00 | 46.00 | 44.00 | 46.00 | 59.00 | 66.00 | 72.00 | 77.00 | 71.00 | 68.00 | 65.00 | 61.00 | 58.00 | 56.00 |
| R&D Expenses | 5.8% | 77.00 | 73.00 | 67.00 | 54.00 | 46.00 | 39.00 | 36.00 | 33.00 | 32.00 | 33.00 | 34.00 | 72.00 | 95.00 | 120 | 141 | 132 | 137 | 144 | 150 | 155 | 153 |
| EBITDA | -100.0% | - | 255 | 272 | 252 | 245 | 305 | 259 | 281 | 246 | 184 | 153 | 44.00 | -19.82 | -62.49 | -56.56 | - | - | - | - | - | - |
| EBITDA Margin | -100.0% | - | 0.36* | 0.41* | 0.43* | 0.50* | 0.65* | 0.58* | 0.61* | 0.60* | 0.55* | 0.57* | 0.22* | -0.11* | -0.38* | -0.29* | - | - | - | - | - | - |
| Interest Expenses | 7.0% | 21.00 | 20.00 | 17.00 | 14.00 | 9.00 | 7.00 | 8.00 | 11.00 | 14.00 | 17.00 | 20.00 | 19.00 | 16.00 | 14.00 | 12.00 | 12.00 | 14.00 | 16.00 | 18.00 | 20.00 | 21.00 |
| Earnings Before Taxes | 27.8% | 290 | 227 | 249 | 233 | 233 | 295 | 249 | 267 | 229 | 163 | 129 | 22.00 | -39.68 | -80.16 | -72.25 | -39.60 | -42.45 | -50.70 | -79.79 | 44.00 | 75.00 |
| EBT Margin | -100.0% | - | 0.32* | 0.38* | 0.40* | 0.48* | 0.63* | 0.56* | 0.58* | 0.56* | 0.49* | 0.48* | 0.11* | -0.22* | -0.49* | -0.37* | - | - | - | - | - | - |
| Net Income | 28.7% | 234 | 182 | 202 | 211 | 366 | 435 | 403 | 409 | 229 | 163 | 129 | 22.00 | -39.70 | -80.14 | -72.24 | -39.97 | -42.80 | -51.07 | -80.33 | 46.00 | 76.00 |
| Net Income Margin | -100.0% | - | 0.26* | 0.31* | 0.36* | 0.75* | 0.92* | 0.91* | 0.88* | 0.55* | 0.49* | 0.48* | 0.11* | -0.22* | -0.49* | -0.37* | - | - | - | - | - | - |
| Free Cashflow | -100.0% | - | 264 | 235 | 238 | 290 | 287 | 298 | 265 | 150 | 116 | 53.00 | -23.54 | -60.14 | -89.07 | -89.46 | - | - | - | - | - | - |
Balance Sheet(In Millions)
| Balance Sheet | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Assets | 6.5% | 1,810 | 1,699 | 1,842 | 1,865 | 1,781 | 1,162 | 1,104 | 1,185 | 1,026 | 967 | 580 | 524 | 527 | 492 | 566 | 370 | 418 | 429 | 440 | 445 | 475 |
| Current Assets | 24.5% | 766 | 615 | 739 | 653 | 542 | 989 | 926 | 1,017 | 1,000 | 942 | 555 | 499 | 500 | 468 | 543 | 342 | 392 | 409 | 428 | 430 | 462 |
| Cash Equivalents | 129.5% | 221 | 96.00 | 234 | 147 | 91.00 | 118 | 119 | 492 | 447 | 500 | 148 | 66.00 | 134 | 105 | 121 | 60.00 | 68.00 | 61.00 | 58.00 | 56.00 | 56.00 |
| Inventory | 23.1% | 132 | 108 | 100 | 103 | 98.00 | 48.00 | 54.00 | 56.00 | 59.00 | 58.00 | 61.00 | 58.00 | 48.00 | 41.00 | 29.00 | 36.00 | 44.00 | 31.00 | 23.00 | 18.00 | 8.00 |
| Net PPE | - | - | - | - | - | - | - | - | - | 10.00 | 10.00 | 11.00 | 10.00 | 11.00 | 12.00 | 11.00 | 15.00 | 15.00 | 15.00 | 7.00 | 7.00 | 5.00 |
| Goodwill | 0.1% | 417 | 416 | 409 | 199 | 199 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Liabilities | 1.6% | 1,659 | 1,634 | 1,672 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Current Liabilities | 26.6% | 116 | 92.00 | 131 | 109 | 200 | 112 | 117 | 113 | 114 | 107 | 421 | 27.00 | 26.00 | 42.00 | 86.00 | 108 | 135 | 139 | 149 | 139 | 132 |
| Long Term Debt | - | - | - | 1,493 | - | 1,147 | 788 | 787 | 786 | 786 | 785 | - | 394 | 390 | 387 | 383 | 9.00 | 14.00 | 19.00 | 35.00 | 58.00 | 79.00 |
| LT Debt, Current | - | - | - | 13.00 | 13.00 | 99.00 | 90.00 | 89.00 | 89.00 | 89.00 | 89.00 | 397 | - | - | 3.00 | 20.00 | 55.00 | 71.00 | 87.00 | 92.00 | 89.00 | 87.00 |
| LT Debt, Non Current | 0.1% | 1,496 | 1,494 | 1,493 | 1,491 | - | - | 787 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Shareholder's Equity | 129.4% | 151 | 66.00 | 170 | 97.00 | 293 | 260 | 197 | 282 | 120 | 68.00 | 151 | 99.00 | 106 | 58.00 | 92.00 | 245 | 260 | 260 | 249 | 240 | 255 |
| Retained Earnings | 113.8% | 140 | 66.00 | 143 | 86.00 | 24.00 | 1.00 | -58.91 | -125 | -342 | -433 | -474 | -547 | -583 | -609 | -603 | -569 | -544 | -529 | -531 | -529 | -501 |
| Additional Paid-In Capital | - | 12.00 | - | 27.00 | 13.00 | 271 | 262 | 256 | 407 | 462 | 501 | 625 | 646 | 688 | 668 | 695 | 814 | 804 | 789 | 780 | 769 | 757 |
| Shares Outstanding | 0.1% | 132 | 132 | 135 | 135 | 138 | 138 | 137 | 142 | 142 | 138 | 135 | 137 | 136 | 137 | 137 | 146 | 145 | 145 | 145 | 144 | 144 |
Cashflow (Last 12 Months)(In Millions)
| Cashflow (Last 12 Months) | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Cashflow From Operations | 9.5% | 306 | 279 | 240 | 240 | 292 | 289 | 299 | 268 | 152 | 119 | 55.00 | -22.09 | -57.76 | -85.84 | -85.42 | -48.34 | -37.67 | -31.75 | -49.50 | 93.00 | 132 |
| Share Based Compensation | 14.4% | 32.00 | 28.00 | 24.00 | 22.00 | 21.00 | 21.00 | 21.00 | 20.00 | 19.00 | 18.00 | 17.00 | 20.00 | 24.00 | 30.00 | 35.00 | 37.00 | 37.00 | 37.00 | 36.00 | 34.00 | 33.00 |
| Cashflow From Investing | 98.4% | -7.92 | -497 | -487 | -784 | -800 | -410 | -406 | -48.38 | -61.52 | -5.00 | 78.00 | -102 | -31.81 | 4.00 | -5.55 | 128 | 122 | 67.00 | 2.00 | -157 | -162 |
| Cashflow From Financing | -185.3% | -168 | 197 | 362 | 200 | 152 | -260 | 78.00 | 206 | 223 | 281 | -106 | 132 | 156 | 126 | 153 | -75.56 | -72.73 | -72.88 | -63.80 | -45.36 | -29.83 |
| Buy Backs | 0% | 350 | 350 | 200 | 267 | 86.00 | 151 | - | 230 | 224 | 177 | 150 | 312 | 254 | 252 | 200 | - | - | - | - | - | - |
HALO Income Statement
2023-06-30Condensed Consolidated Statements of Income (Unaudited) - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
| Revenues | ||||
| Total revenues | $ 221,038 | $ 152,365 | $ 383,181 | $ 269,644 |
| Operating expenses | ||||
| Cost of sales | 50,070 | 33,943 | 85,240 | 49,865 |
| Amortization of intangibles | 17,835 | 11,403 | 35,670 | 11,403 |
| Research and development | 19,727 | 15,483 | 37,706 | 27,336 |
| Selling, general and administrative | 38,948 | 57,476 | 76,305 | 71,310 |
| Total operating expenses | 126,580 | 118,305 | 234,921 | 159,914 |
| Operating income | 94,458 | 34,060 | 148,260 | 109,730 |
| Other income (expense) | ||||
| Investment and other income (expense), net | 3,192 | (945) | 6,171 | (447) |
| Interest expense | (4,494) | (3,104) | (9,037) | (4,863) |
| Net income before income taxes | 93,156 | 30,011 | 145,394 | 104,420 |
| Income tax expense | 18,402 | 7,326 | 31,025 | 21,627 |
| Net income | $ 74,754 | $ 22,685 | $ 114,369 | $ 82,793 |
| Earnings per share | ||||
| Basic (USD per share) | $ 0.57 | $ 0.16 | $ 0.86 | $ 0.60 |
| Diluted (USD per share) | $ 0.56 | $ 0.16 | $ 0.84 | $ 0.58 |
| Weighted average common shares outstanding | ||||
| Basic (shares) | 131,730 | 137,937 | 133,369 | 137,798 |
| Diluted (shares) | 133,543 | 142,216 | 135,758 | 141,795 |
| Royalties | ||||
| Revenues | ||||
| Total revenues | $ 111,740 | $ 85,340 | $ 211,380 | $ 154,945 |
| Product sales, net | ||||
| Revenues | ||||
| Total revenues | 73,889 | 46,300 | 134,683 | 68,440 |
| Revenues under collaborative agreements | ||||
| Revenues | ||||
| Total revenues | $ 35,409 | $ 20,725 | $ 37,118 | $ 46,259 |
HALO Balance Sheet
2023-06-30Condensed Consolidated Balance Sheets (Unaudited) - USD ($) | Jun. 30, 2023 | Dec. 31, 2022 |
|---|---|---|
| Current assets | ||
| Cash and cash equivalents | $ 221,165,000 | $ 234,195,000 |
| Marketable securities, available-for-sale | 127,110,000 | 128,599,000 |
| Accounts receivable, net and contract assets | 246,179,000 | 231,072,000 |
| Inventories, net | 132,406,000 | 100,123,000 |
| Prepaid expenses and other current assets | 38,885,000 | 45,024,000 |
| Total current assets | 765,745,000 | 739,013,000 |
| Property and equipment, net | 74,559,000 | 75,570,000 |
| Prepaid expenses and other assets | 18,409,000 | 26,301,000 |
| Goodwill | 416,821,000 | 409,049,000 |
| Intangible assets, net | 510,982,000 | 546,652,000 |
| Deferred tax assets, net | 23,924,000 | 44,426,000 |
| Restricted cash | 0 | 500,000 |
| Total assets | 1,810,440,000 | 1,841,511,000 |
| Current liabilities | ||
| Accounts payable | 10,120,000 | 17,693,000 |
| Accrued expenses | 105,431,000 | 96,516,000 |
| Deferred revenue, current portion | 842,000 | 3,246,000 |
| Current portion of long-term debt, net | 0 | 13,334,000 |
| Total current liabilities | 116,393,000 | 130,789,000 |
| Deferred revenue, net of current portion | 2,253,000 | 2,253,000 |
| Long-term debt, net | 1,495,998,000 | 1,492,766,000 |
| Other long-term liabilities | 30,875,000 | 30,433,000 |
| Contingent liability | 13,888,000 | 15,472,000 |
| Total liabilities | 1,659,407,000 | 1,671,713,000 |
| Commitments and contingencies (Note 12) | ||
| Stockholders’ equity | ||
| Preferred stock - $0.001 par value; 20,000 shares authorized; no shares issued and outstanding | 0 | 0 |
| Common stock - $0.001 par value; 300,000 shares authorized; 131,856 and 135,154 shares issued and outstanding as of June 30, 2023 and December 31, 2022, respectively | 132,000 | 135,000 |
| Additional paid-in capital | 12,068,000 | 27,368,000 |
| Accumulated other comprehensive loss | (1,615,000) | (922,000) |
| Retained earnings | 140,448,000 | 143,217,000 |
| Total stockholders’ equity | 151,033,000 | 169,798,000 |
| Total liabilities and stockholders’ equity | $ 1,810,440,000 | $ 1,841,511,000 |
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its flagship product is Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in subcutaneous urography and to improve resorption of radiopaque agents. The company also develops Perjeta; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; Horizon Therapeutics plc; National Institute of Allergy and Infectious Diseases; Centre for the AIDS Programme of Research in South Africa; and ViiV Healthcare Limited for small and large molecule targets for the treatment and prevention of HIV. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.